{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:23:36Z","timestamp":1785777816322,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Cancer Organizations"},{"DOI":"10.13039\/100007634","name":"Ida Montinin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007634","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Society for Oncology Weikko Peltonen Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Marginal zone lymphoma (MZL) is an indolent B-cell malignancy with heterogeneous anatomical and clinical presentation. While MZLs are generally associated with long survival, some patients experience histological transformation to aggressive large B-cell lymphoma. Population-based long-term data on the transformation of MZL is limited. We conducted a nationwide population-based study to estimate the risk of transformation and relative survival in patients diagnosed with MZL in Finland from 1995\u20132018. We identified a total of 1454 patients with MZL from the Finnish Cancer Registry (FCR). The cumulative incidence of transformation was 4.7% (95% CI, 3.6\u22126.2) at 10 years. The highest incidence of transformation was observed in the patients with splenic MZL (14.0%; 95% CI, 8.6\u221222.7). The transformation was associated with a substantially increased risk of death (HR, 5.18; 95% CI, 3.58\u20137.50). Ten-year relative survival was 79% (95% CI, 73\u201283%). Transformation, nodal MZL subtype, and older age at diagnosis were associated with increased excess mortality, whereas patients diagnosed at a later calendar period had a lower excess risk of death. We conclude that transformation resulted in a substantially increased mortality irrespective of MZL subtype compared with the patients without transformation. Our results also suggest a reduction in excess mortality in recent years.<\/jats:p>","DOI":"10.1038\/s41408-023-00831-9","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:02:20Z","timestamp":1682395340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-3907","authenticated-orcid":false,"given":"Ilja","family":"Kalashnikov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-1810","authenticated-orcid":false,"given":"Tomas","family":"Tanskanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leevi","family":"Viisanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8127-8087","authenticated-orcid":false,"given":"Nea","family":"Malila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirkku","family":"Jyrkki\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"831_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","volume":"31","author":"E Zucca","year":"2020","unstructured":"Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:17\u201329.","journal-title":"Ann Oncol"},{"key":"831_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, de O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"831_CR3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"831_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.12730","volume":"165","author":"MO Khalil","year":"2014","unstructured":"Khalil MO, Morton LM, Devesa SS, Check DP, Curtis RE, Weisenburger DD, et al. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol. 2014;165:67\u201377.","journal-title":"Br J Haematol"},{"key":"831_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3109\/10428194.2014.956315","volume":"56","author":"M Dandoit","year":"2015","unstructured":"Dandoit M, Mounier M, Guy J, Petrella T, Girard S, Casasnovas R-O, et al. The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry. Leuk Lymphoma. 2015;56:1050\u20137.","journal-title":"Leuk Lymphoma"},{"key":"831_CR6","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/ijc.28849","volume":"135","author":"MT van Leeuwen","year":"2014","unstructured":"van Leeuwen MT, Turner JJ, Joske DJ, Falster MO, Srasuebkul P, Meagher NS, et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. Int J Cancer. 2014;135:2146\u201356.","journal-title":"Int J Cancer"},{"key":"831_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575\u201384.","journal-title":"Br J Cancer"},{"key":"831_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cncr.27773","volume":"119","author":"AJ Olszewski","year":"2013","unstructured":"Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database. Cancer. 2013;119:629\u201338.","journal-title":"Cancer"},{"key":"831_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.beha.2016.08.029","volume":"30","author":"C Casulo","year":"2017","unstructured":"Casulo C, Friedberg J. Transformation of marginal zone lymphoma (and association with other lymphomas). Best Pr Res Clin Haematol. 2017;30:131\u20138.","journal-title":"Best Pr Res Clin Haematol"},{"key":"831_CR10","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J. Clin. Oncol. 2018; JCO1800138.","DOI":"10.1200\/JCO.18.00138"},{"key":"831_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/annonc\/mdt507","volume":"25","author":"AH Meyer","year":"2014","unstructured":"Meyer AH, Stroux A, Lerch K, Eucker J, Eitle J, Hohloch K, et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol J Eur Soc Med Oncol. 2014;25:210\u20135.","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"831_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/bjh.14153","volume":"174","author":"AM Maeshima","year":"2016","unstructured":"Maeshima AM, Taniguchi H, Toyoda K, Yamauchi N, Makita S, Fukuhara S, et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol. 2016;174:923\u201331.","journal-title":"Br J Haematol"},{"key":"831_CR13","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","volume":"26","author":"A Conconi","year":"2015","unstructured":"Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia AA, et al. Histologic transformation in marginal zone lymphomas\u2020. Ann Oncol J Eur Soc Med Oncol. 2015;26:2329\u201335.","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"831_CR14","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Vol. 2. Lyon: International Agency for Research on Cancer; 2017."},{"key":"831_CR15","unstructured":"Fritz AG, editor. International classification of diseases for oncology: ICD-O. 3rd ed. First revision. Geneva: World Health Organization; 2013."},{"key":"831_CR16","unstructured":"World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death based on the recommendations of the seventh revision Conference, 1955, and adopted by the ninth World Health Assembly under the WHO Nomenclature Regulations. (1957). https:\/\/apps.who.int\/iris\/handle\/10665\/42900."},{"key":"831_CR17","unstructured":"American Cancer Society. Manual of tumor nomenclature and coding. New York: American Cancer Society; 1951."},{"key":"831_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/0284186X.2017.1407039","volume":"57","author":"E Pukkala","year":"2018","unstructured":"Pukkala E, Engholm G, H\u00f8jsgaard Schmidt LK, Storm H, Khan S, Lambe M, et al. Nordic Cancer Registries - an overview of their procedures and data comparability. Acta Oncol Stock Swed. 2018;57:440\u201355.","journal-title":"Acta Oncol Stock Swed"},{"key":"831_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2017.02.017","volume":"77","author":"MK Leinonen","year":"2017","unstructured":"Leinonen MK, Miettinen J, Heikkinen S, Pitk\u00e4niemi J, Malila N. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer Oxf Engl. 2017;77:31\u201339.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"831_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361\u201392.","journal-title":"Blood"},{"key":"831_CR21","unstructured":"Official Statistics of Finland (OSF). Causes of death [e-publication]. ISSN=1799-5078. Helsinki: Statistics Finland [referred: 5.3.2023]. http:\/\/www.stat.fi\/til\/ksyyt\/ksyyt_2021-10-29_luo_001_en.html."},{"key":"831_CR22","unstructured":"Ederer F, Heise H . Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. Bethesda: National Cancer Institute; 1959."},{"key":"831_CR23","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#","volume":"78","author":"H Brenner","year":"1996","unstructured":"Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78:2004\u201310.","journal-title":"Cancer"},{"key":"831_CR24","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1002\/sim.3064","volume":"26","author":"CP Nelson","year":"2007","unstructured":"Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med. 2007;26:5486\u201398.","journal-title":"Stat Med"},{"key":"831_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canep.2018.10.017","volume":"58","author":"E Syriopoulou","year":"2019","unstructured":"Syriopoulou E, Mozumder SI, Rutherford MJ, Lambert PC. Robustness of individual and marginal model-based estimates: a sensitivity analysis of flexible parametric models. Cancer Epidemiol. 2019;58:17\u201324.","journal-title":"Cancer Epidemiol"},{"key":"831_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.2021.278755","volume":"107","author":"CY Cheah","year":"2022","unstructured":"Cheah CY, Zucca E, Rossi D, Habermann TM. Marginal zone lymphoma: present status and future perspectives. Haematologica. 2022;107:35\u201343.","journal-title":"Haematologica"},{"key":"831_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/aol-20-28","volume":"5","author":"JR Cerhan","year":"2021","unstructured":"Cerhan JR, Habermann TM. Epidemiology of marginal zone lymphoma. Ann Lymphoma. 2021;5:1.","journal-title":"Ann Lymphoma"},{"key":"831_CR28","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1182\/bloodadvances.2022007990","volume":"6","author":"AM Tun","year":"2022","unstructured":"Tun AM, Khurana A, Mwangi R, Link BK, Wang Y, Feldman AL, et al. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Adv. 2022;6:5210\u201321.","journal-title":"Blood Adv"},{"key":"831_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/bjh.13320","volume":"169","author":"KH Xing","year":"2015","unstructured":"Xing KH, Kahlon A, Skinnider BF, Connors JM, Gascoyne RD, Sehn LH, et al. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol. 2015;169:520\u20137.","journal-title":"Br J Haematol"},{"key":"831_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jclinepi.2003.12.008","volume":"57","author":"C van Walraven","year":"2004","unstructured":"van Walraven C, Davis D, Forster AJ, Wells GA. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol. 2004;57:672\u201382.","journal-title":"J Clin Epidemiol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00831-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00831-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00831-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:03:12Z","timestamp":1682395392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00831-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00831-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"COMPETING INTERESTS"}}],"article-number":"62"}}